Translation Acceleration Grant to Validate Predictive Markers for Treatment Response and Outcome
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire with Unit
Memorial Deadline: Tuesday 3rd, July 2018
External Deadline: Monday 9th, July 2018
Description
Prostate Cancer Canada (PCC) invites applications for investigator-initiated Movember Translation Acceleration Grants (TAG).
With more treatments coming on line, there is a greater need to assess who will benefit most from each treatment. Projects funded by this TAG mechanism will validate existing putative markers or tests in patient samples, either retrospectively or within a clinical trial. Assays can be biospecimen or imaging markers or other appropriate tests including histology or bioinformatics.
This request for applications (RFA) solicits proposals from groups developing and validating methods to specifically and accurately predict treatment response and/or patient outcome using an appropriate assay. The end goal is clinical validation of the approach and more accurate and personalized selection of treatments for patients with prostate cancer.
It is expected that a multidisciplinary approach will be required and each Movember TAG application may consist of independent investigators based in multiple institutions. PCC also strongly encourages, wherever possible, that applications would access and use existing banked clinical specimens. PCC will only consider projects that are completely focused on prostate cancer.
Additional information and support documents are available on the PCC website and within the online application.
Key Dates:
Access to the Online Application: now
Registration Deadline: Tuesday, May 15, 2018 at 5 pm Eastern
Full Application Deadline: Monday, July 9, 2018 at 5 pm Eastern
Funding Start Date: October 1, 2018